ATNM · XBRL financial data

Actinium Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ATNM's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	year only	—	—	—	—	—	—	90	0*	—	35,000
Research and development	11,622	8,118*	6,635	8,825	9,774	4,811*	7,700	4,879	4,248	4,297*	4,201	5,377
General and administrative	2,729	2,306*	2,962	3,593	2,827	2,694*	8,938	2,624	1,534	2,117*	1,702	2,058
Total operating expenses	14,351	10,424*	9,597	12,418	12,601	7,505*	16,638	7,503	5,782	6,414*	5,903	7,435
Operating income (loss)	(14,351)	(10,343)*	(9,597)	(12,418)	(12,601)	(7,505)*	(16,638)	(7,503)	(5,692)	(6,414)*	(5,903)	27,565
Interest income	1,075	1,019*	927	1,065	1,033	853*	700	625	561	474*	381	336
Net income (loss)	(13,276)	(9,324)*	(8,670)	(11,353)	(11,568)	(6,652)*	(15,938)	(6,878)	(5,131)	(5,940)*	(5,522)	27,901
Earnings per share, basic USD per share	(0.49)	(0.34)*	(0.31)	(0.38)	(0.37)	(0.21)*	(0.51)	(0.22)	(0.16)	(0.19)*	(0.18)	0.89
Earnings per share, diluted USD per share	(0.49)	(0.34)*	(0.31)	(0.38)	(0.37)	(0.21)*	(0.51)	(0.22)	(0.16)	(0.19)*	(0.18)	0.89
Weighted average shares, basic thousands of shares	27,058	27,419*	27,886	30,103	31,071	31,196*	31,196	31,196	31,196	31,196*	31,238	31,399
Weighted average shares, diluted thousands of shares	27,058	27,419*	27,886	30,103	31,071	31,196*	31,196	31,196	31,196	31,196*	31,238	31,407

Fiscal quarters (ATNM's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	82,978	76,677	84,057	86,037	78,660	72,904	65,325	59,928	53,391	47,998	42,132	36,473
Prepaid and other current assets	2,618	1,586	1,316	1,031	860	1,602	1,131	1,101	975	1,383	1,129	1,267
Total current assets	85,596	78,263	85,373	87,068	79,520	74,506	66,456	61,029	54,366	49,381	43,261	37,740
Property and equipment, net	601	550	496	460	412	364	317	271	226	295	268	700
Right-of-use asset	2,436	2,289	2,140	1,990	1,838	1,685	1,530	1,373	1,215	1,754	1,565	1,373
Total assets	88,944	81,445	88,352	89,861	82,114	76,899	68,647	63,017	56,151	51,775	45,438	40,157
Total current liabilities	8,672	8,494	8,064	9,728	7,755	8,148	7,110	8,314	6,834	7,969	7,349	9,260
Lease liability, non-current	1,689	1,553	1,414	1,284	1,139	984	836	685	531	972	785	595
Total liabilities	45,361	45,066	44,495	46,026	43,906	44,141	42,953	44,004	42,367	43,941	43,134	9,855
Accumulated deficit	(328,259)	(337,583)	(346,253)	(357,606)	(369,174)	(375,826)	(391,764)	(398,642)	(403,773)	(409,713)	(415,235)	(387,334)
Total stockholders' equity	43,583	36,379	43,857	43,835	38,208	32,758	25,694	19,013	13,784	7,834	2,304	30,302
Total liabilities and equity	88,944	81,445	88,352	89,861	82,114	76,899	68,647	63,017	56,151	51,775	45,438	40,157
Common shares outstanding (cover page) thousands of shares	27,413	29,396	29,783	31,154	31,196	31,196	31,196	31,196	31,196	31,375	31,375	31,441

Fiscal quarters (ATNM's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(13,276)	(9,324)*	(8,670)	(11,353)	(11,568)	(6,652)*	(15,938)	(6,878)	(5,131)	(5,940)*	(5,522)	27,901
Stock-based compensation	921*	927*	1,378	1,374*	1,337*	1,203*	8,874	197*	109*	10*	11	118*
Depreciation and amortization	—	—	216	189*	202*	(410)*	205	204*	206*	(442)*	29	432*
Net cash from operating activities	(11,125)*	(7,490)*	(7,374)	(7,972)*	(11,975)*	(5,751)*	(7,574)	(5,392)*	(6,325)*	(5,289)*	(5,870)	(5,179)*
Purchases of property and equipment	30*	0*	11	0*	0*	0*	—	—	—	year only	2	478*
Net cash from investing activities	(30)*	0*	(11)	0*	0*	0*	—	—	—	year only	(2)	(478)*
Proceeds from issuing common stock	2,861*	1,193*	14,695	9,957*	4,604*	(1)*	—	—	—	—	—	—
Net cash from financing activities	2,860*	1,192*	14,768	9,954*	4,602*	(3)*	(2)	(3)*	(209)*	(3)*	(3)	(2)*
Net change in cash	—	—	—	—	—	year only	(7,576)	(5,395)*	—	year only	(5,864)	(5,657)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Actinium Pharmaceuticals	36,473	35,000	(5,179)*	31.4M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Fortress Biotech	196,576	18,718	(59,277)*	33.3M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Lite Strategy	5,706	not reported	(1,164)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026
Actuate Therapeutics	4,426	not reported	(4,405)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
CervoMed	22,463	0	(6,918)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Atara Biotherapeutics	3,221	630	(3,338)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.